|Day Low/High||4.88 / 5.25|
|52 Wk Low/High||3.95 / 9.25|
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Novel approach using ALK2 inhibition
The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 1,191,695 share increase in total short interest for BioCryst Pharmaceuticals, Inc. , to 12,007,211, an increase of 11.02% since 11/15/2017.
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.
Investors considering a purchase of BioCryst Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.
The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon Stonehouse in the news release.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the August 18th expiration.
BioCryst Pharmaceuticals, Omeros and Radius Health were among the were among the biotech stock movers in premarket trading on July 3.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.